킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American Academy of Allergy Asthma and Immunology/World Allergy Organization Joint Congress (AAAAI/WAO Joint Congress 2025)

28 February - 03 March, 2025, United States

Children with food allergies at risk of stunting, but immunotherapy helps

2025-03-24

Eliminating certain foods such as egg and milk from children’s diet due to IgE-mediated allergy may hinder growth, but oral immunotherapy helps improve growth trajectories, especially when initiated at a younger age, according to two studies.
Could early formula feeding be promoting infant food allergies?

2025-03-24

Newborns who are not exclusively fed colostrum within the first 3 days of life may have a higher likelihood of developing food allergies, according to a study.
Dupilumab eases itch, disease activity in chronic spontaneous urticaria

2025-03-24

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.
Lebrikizumab improves anxiety, depression symptoms in adolescents with AD

2025-03-24

Lebrikizumab improves anxiety and depression symptoms, as shown by PROMIS* scores, in patients with moderate-to-severe atopic dermatitis (AD), according to the ADore trial presented at AAAAI/WAO 2025.
Omalizumab continues to OUtMATCH OIT in updated analysis

2025-03-24

Omalizumab remains superior to oral immunotherapy (OIT) for the treatment of multi-food allergies with fewer adverse effects in Stage 2 of the NIH*-sponsored phase III OUtMATCH** study, the first head-to-head trial comparing the two treatments.
Ruxolitinib cream shows benefit in patients with AD, regardless of age

2025-03-24

Twice-daily application of ruxolitinib cream monotherapy appears effective and well tolerated in the treatment of mild-to-moderate atopic dermatitis (AD), regardless of age, based on a pooled analysis of three phase III trials presented at AAAAI/WAO 2025.
Sublingual film a reliable lifeline for life-threatening allergic reactions?

2025-03-24

Data presented at AAAAI/WAO 2025 verify the potential of the epinephrine sublingual film (ESF) Anaphylm for the treatment of type 1 allergic reactions, including anaphylaxis.
Twice-yearly depemokimab safe, effective in chronic rhinosinusitis with nasal polyps

2025-03-24

Treatment with two doses of depemokimab results in sufficient concentrations to adequately control blood eosinophil counts (BEC) over 1 year, as shown in the ANCHOR 1 and 2 trials. This finding suggests sustained anti-interleukin-5 (IL-5) biological effect and impact on type 2 inflammation.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브